Vildaglip
Generic Name
Vildagliptin 50 mg Tablet
Manufacturer
Example Pharmaceutical Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vildaglip 50 mg tablet | ৳ 12.00 | ৳ 120.00 |
Description
Overview of the medicine
Vildagliptin is an oral anti-diabetic medication used for the treatment of type 2 diabetes mellitus. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones in the body.
Uses & Indications
Dosage
Adults
The recommended dose is 50 mg once or twice daily, depending on individual efficacy and tolerability. When used with a sulfonylurea, 50 mg once daily is usually sufficient.
Elderly
No dose adjustment is required in elderly patients.
Renal_impairment
In patients with moderate to severe renal impairment (CrCl < 50 mL/min), including end-stage renal disease (ESRD) on dialysis, the recommended dose is 50 mg once daily.
How to Take
Vildagliptin tablets can be taken orally, with or without food. The tablet should be swallowed whole with water.
Mechanism of Action
Vildagliptin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the inactivation of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, vildagliptin increases the levels of active GLP-1 and GIP, leading to enhanced glucose-dependent insulin secretion from pancreatic beta cells and reduced glucagon secretion from pancreatic alpha cells. This results in improved glycemic control.
Pharmacokinetics
Onset
Rapid, typically within 1-2 hours of administration.
Excretion
Approximately 85% of the dose is excreted via the kidneys (23% as unchanged drug) and 15% via the feces.
Half life
The elimination half-life is approximately 3 hours.
Absorption
Rapidly absorbed after oral administration, with an absolute oral bioavailability of 85%. Peak plasma concentrations occur at 1.7 hours.
Metabolism
Primarily metabolized by hydrolysis (69% of the dose) with the major metabolite being LAY151. CYP450 enzymes are minimally involved.
Side Effects
Contraindications
- •Hypersensitivity to the active substance or to any of the excipients.
- •Patients with severe heart failure (NYHA class III-IV).
- •Patients with hepatic impairment.
Drug Interactions
ACE Inhibitors
Increased risk of angioedema when co-administered with ACE inhibitors.
Digoxin, Warfarin, Amlodipine, Ramipril
Vildagliptin does not significantly interact with these commonly co-administered drugs.
Thiazides, Corticosteroids, Thyroid products
May reduce the glucose-lowering effect of Vildagliptin.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, supportive treatment should be initiated as appropriate for the patient's clinical state. Vildagliptin can be partially removed by hemodialysis.
Pregnancy & Lactation
Vildagliptin is not recommended during pregnancy or lactation unless the potential benefit outweighs the potential risk to the fetus or infant. Consult a doctor.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
2-3 years from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
Approved
Patent Status
Off-patent in many regions
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in